Kirin Holdings Co Ltd (KIR.SG)
| Previous close | 12.50 |
| Open | 12.20 |
| Bid | 12.00 x N/A |
| Ask | 12.30 x N/A |
| Day's range | 12.20 - 12.30 |
| 52-week range | 12.20 - 13.91 |
| Volume | |
| Avg. volume | 16 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary
TOKYO, June 14, 2024--Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has decided to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and share warrants under the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended) with to make FANCL a wholly-owned subsidiary.
- Business Wire
Kirin Holdings will begin online sales of "Electric Salt Spoon", a spoon that uses electricity to enhance salty and umami taste*1, on May 20
TOKYO, May 20, 2024--Kirin Holdings Company, Limited (Kirin) will launch as a new business in the Health Science domain (Health Science business) a limited offering of 200 units of Electric Salt Spoon, which enhances the salty and umami taste of low-sodium foods with the power of electricity, on Monday, May 20, 2024 at its official online store (https://electricsalt.shop.kirin.co.jp/). In addition, a limited number of units will be available at Hands Inc. stores beginning in June.This tableware-
- Business Wire
LC-Plasma-based Vaccine Research Selected for SCARDA Project
TOKYO, May 08, 2024--Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis strain Plasma [postbiotic] (LC-Plasma) immunization against infectious diseases. We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strat
